A surfactant formulation engineering approach using the Hydrophilic/Lipophilic Deviation (HLD) method to design cationic-free antimicrobial systems that disrupt microbial cell membranes and viral envelopes. This technology enables creation of optimized surfactant formulations for disinfection without relying on cationic surfactants.
This research proposes a novel formulation engineering approach for designing antimicrobial and antiviral surfactant systems using the Hydrophilic/Lipophilic Deviation (HLD) method. The core insight treats microbial phospholipid bilayers as an oil phase, enabling the design of surfactant systems that create Winsor III microemulsions with these bilayers. Under these formulation conditions, surfactant adsorption onto the bilayer destroys the membrane structure, effectively killing microorganisms or deactivating viruses without requiring cationic surfactants.
This approach offers a promising alternative to traditional cationic surfactant-based disinfectants, potentially reducing formulation costs, minimizing environmental impact, and addressing concerns about cationic surfactant resistance or sensitivity. Applications include surface disinfection, antimicrobial coatings, sanitization products, and antiviral treatments for healthcare, food safety, and consumer products.
Key technical features:
Research approach:
This technology is at an early research stage (TRL 2-3). The HLD equation has been previously validated for designing surfactant formulations for solid non-particulate soils, as demonstrated in published research on detergency correlations. However, the method has not yet been applied to disinfectant design. Future validation will begin with EACN measurements of representative phospholipids, followed by formulation design and proof-of-concept testing through detergency and disinfection efficiency studies.
The University of Oklahoma is a flagship public research university spanning Norman, Oklahoma City, and Tulsa, combining comprehensive academics with a major health sciences center. Industry collaborates through a research and technology campus in Norman that co‑locates university facilities with federal partners, and through the OU Health Sciences Center, which connects clinicians, core labs, and clinical trials within the OU Health system. Dedicated corporate engagement and contracting teams streamline sponsored research, while a centralized technology commercialization office supports IP, licensing, and startup formation. Research is supported by competitive federal funding from agencies such as NIH, NSF, DOE, and DoD.